Welcome to LookChem.com Sign In|Join Free
  • or
1-{[2-(2-fluorophenyl)-3-oxo-2,3-dihydro-1H-benzo[e]isoindol-5-yl]methyl}-4-pyridin-2-ylpiperidine-4-carbonitrile is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

1414366-63-4

Post Buying Request

1414366-63-4 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1414366-63-4 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 1414366-63-4 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,4,1,4,3,6 and 6 respectively; the second part has 2 digits, 6 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 1414366-63:
(9*1)+(8*4)+(7*1)+(6*4)+(5*3)+(4*6)+(3*6)+(2*6)+(1*3)=144
144 % 10 = 4
So 1414366-63-4 is a valid CAS Registry Number.

1414366-63-4Downstream Products

1414366-63-4Relevant academic research and scientific papers

Discovery of naphthyl-fused 5-membered lactams as a new class of M 1 positive allosteric modulators

Yang, Zhi-Qiang,Shu, Youheng,Ma, Lei,Wittmann, Marion,Ray, William J.,Seager, Matthew A.,Koeplinger, Kenneth A.,Thompson, Charles D.,Hartman, George D.,Bilodeau, Mark T.,Kuduk, Scott D.

, p. 604 - 608 (2014/06/09)

Selective activation of the M1 muscarinic receptor via positive allosteric modulation represents an original approach to treat the cognitive decline in patients with Alzheimer's disease. A series of naphthyl-fused 5-membered lactams were identified as a new class of M1 positive allosteric modulators and were found to possess good potency and in vivo efficacy.

N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS

-

Page/Page column 72, (2012/12/13)

The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 1414366-63-4